329 related articles for article (PubMed ID: 36601001)
1.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
2. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel.
Li H; Wang X; Zhai M; Xu C; Chen X
Discov Oncol; 2024 May; 15(1):152. PubMed ID: 38730195
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
5. The expression of AURKA is androgen regulated in castration-resistant prostate cancer.
Kivinummi K; Urbanucci A; Leinonen K; Tammela TLJ; Annala M; Isaacs WB; Bova GS; Nykter M; Visakorpi T
Sci Rep; 2017 Dec; 7(1):17978. PubMed ID: 29269934
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
[TBL] [Abstract][Full Text] [Related]
7. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
8. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
11. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
12. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
13. Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).
Li Y; Shi H; Zhao Z; Xu M
BMC Urol; 2022 Oct; 22(1):162. PubMed ID: 36258196
[TBL] [Abstract][Full Text] [Related]
14. Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.
Liu J; Zhang R; Su T; Zhou Q; Gao L; He Z; Wang X; Zhao J; Xing Y; Sun F; Cai W; Wang X; Han J; Qin R; Désaubry L; Han B; Chen W
J Exp Clin Cancer Res; 2023 May; 42(1):128. PubMed ID: 37210546
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
[TBL] [Abstract][Full Text] [Related]
16. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
[TBL] [Abstract][Full Text] [Related]
17. CYP1B1-catalyzed 4-OHE2 promotes the castration resistance of prostate cancer stem cells by estrogen receptor α-mediated IL6 activation.
Lin Q; Cao J; Du X; Yang K; Yang X; Liang Z; Shi J; Zhang J
Cell Commun Signal; 2022 Mar; 20(1):31. PubMed ID: 35292057
[TBL] [Abstract][Full Text] [Related]
18. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
19. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
20. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]